Preferential expression of Mdm2 oncogene during the development of neural crest and its derivatives in mouse early embryogenesis.
The Mdm2 oncoprotein acts as the principal negative regulator of p53 activities and is essential for its control during mouse early development, at least before implantation. We analyzed Mdm2 expression between 7.5 and 9 days post-coitum (dpc) by whole-mount in situ hybridization and report here a novel expression pattern during neural crest development. At 7.5 dpc Mdm2 becomes preferentially expressed at the top of the neural folds. Between 8 and 9 dpc, this preferential expression is also observed in neural crest cells migrating from the closing brain towards craniofacial regions and the first three branchial arches. It persists in the craniofacial mesenchyme and the first branchial arch in 9 dpc embryos. Migrating neural crest cells in the tail region are also preferentially labeled at this stage. At day 9.5 Mdm2 becomes more ubiquitously expressed throughout the embryo as reported before.
Daujat
S
S
Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535-IFR 24, 1919 Route de Mende, 34293 Montpellier Cedex 05, France.
Neel
H
H
Piette
J
J
D000818:Animals; D002465:Cell Movement; D018076:DNA, Complementary / Q000378:metabolism; D004622:Embryo, Mammalian / Q000378:metabolism*; D017403:In Situ Hybridization; D008648:Mesoderm / Q000378:metabolism; D051379:Mice; D009432:Neural Crest / Q000378:metabolism*; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D051736:Proto-Oncogene Proteins c-mdm2; D012260:Ribonucleases / Q000378:metabolism; D013997:Time Factors
D018076:DNA, Complementary; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; C497207:Mdm2 protein, mouse; D051736:Proto-Oncogene Proteins c-mdm2; D012260:Ribonucleases